BEDMINSTER, N.J.,
Feb. 21, 2018
/PRNewswire/ -- Mallinckrodt
Pharmaceuticals (NYSE: MNK), a leading global
specialty pharmaceutical company, announced today its new Specialty
Brands office site in Bedminster,
N.J. earned recognition as a 2017 Somerset
County Planning Board Land Development Award honoree in the
Commercial category. Awards were presented Tuesday
evening at the County Administration Building in Somerville.
Mallinckrodt officially opened
its Specialty Brands office in October
2017 at 1405-1425 U.S. Route 206. The office is home to a
workforce of nearly 500 that supports marketed and development
products in the company's hospital and autoimmune and rare diseases
businesses.
"We are pleased to be honored alongside a wide range of
development projects in our community, recognized for high levels
of design and creativity," said Mark
Trudeau, Mallinckrodt President
and Chief Executive Officer. "Bedminster has been an excellent setting for
our company, and significant design and planning efforts have
resulted in the build-out of a collaborative, dynamic work space
for our New Jersey-based employees
and a site that will meet the needs of our fast-transforming
business."
Mallinckrodt's investment
includes a complete renovation of 190,000 square feet of office
space, with the company occupying more than 80 percent of the
building, and design of an open, light-filled work environment
providing multiple ways to work and collaborate. The office complex
had been vacant for several years, and Mallinckrodt led renovation of the buildings into
Class A office space with a full-service cafeteria, fitness center,
and a data center. More than 70 percent of the space is open floor
plan, and the site can accommodate future growth.
New energy-efficient LED lighting replaced older
fluorescent interior lighting, as part of an energy efficient
master lighting control system. Exterior improvements to the
23-acre site included the removal of 75 dead or damaged trees,
planting of 115 new indigenous evergreen and shade trees,
installation of new indigenous ground cover and mulched plant beds,
and upgraded entry paving to meet all accessibility
standards.
A program of the Somerset County Planning Board, the
35th Annual Land Development and Planning Awards Program
sought nominations for projects that are exceptionally
well-designed and planned. Selection criteria were:
- Imaginative planning using a creative, new approach to a
planning issue or concern;
- Innovative site design demonstrating a unique approach to
physical design representing high standards of site planning and
engineering;
- Demonstrated cooperation between local officials and
applicants promoting sound planning practices and public
objectives;
- Adaptive-use projects that retain the original quality or
characteristic form of the building; and
- Projects that showcase innovative, cost-effective energy
conservation and high-efficiency solutions and/or renewable energy
technologies that enhance community sustainability, improve
resiliency, advance sustainability goals, and initiatives, save
energy and reduce greenhouse gas emissions.
To learn more about Mallinckrodt or to explore career opportunities
with the company, visit
www.mallinckrodt.com.
ABOUT MALLINCKRODT
Mallinckrodt is a global business that develops,
manufactures, markets and distributes specialty pharmaceutical
products and therapies. Areas of focus include autoimmune and rare
diseases in specialty areas like neurology, rheumatology,
nephrology, pulmonology and ophthalmology; immunotherapy and
neonatal respiratory critical care therapies; analgesics and
gastrointestinal products. The company's core strengths include the
acquisition and management of highly regulated raw materials and
specialized chemistry, formulation and manufacturing capabilities.
The company's Specialty Brands segment includes branded medicines
and its Specialty Generics segment includes specialty generic
drugs, active pharmaceutical ingredients and external
manufacturing. To learn more about Mallinckrodt, visit
www.mallinckrodt.com.
Mallinckrodt uses its website
as a channel of distribution of important company information, such
as press releases, investor presentations and other financial
information. It also uses its website to expedite public access to
time-critical information regarding the company in advance of or in
lieu of distributing a press release or a filing with the U.S.
Securities and Exchange Commission disclosing the same information.
Therefore, investors should look to the Investor Relations page of
the website for important and time-critical information. Visitors
to the website can also register to receive automatic e-mail and
other notifications alerting them when new information is made
available on the Investor Relations page of the website.
CONTACTS
Media
Rhonda Sciarra
Senior Communications Manager
908-238-6765
rhonda.sciarra@mallinckrodt.com
Meredith Fischer
Chief Public Affairs Officer
314-654-3318
meredith.fischer@mallinckrodt.com
Investor Relations
Coleman N. Lannum, CFA
Senior Vice President, Investor Strategy and IRO
314-654-6649
cole.lannum@mallinckrodt.com
Daniel J. Speciale, CPA
Director, Investor Relations
314-654-3638
daniel.speciale@mallinckrodt.com
Mallinckrodt, the "M"
brandmark and the Mallinckrodt Pharmaceuticals logo are trademarks
of a Mallinckrodt company. Other brands
are trademarks of a Mallinckrodt
company or their respective owners. © 2018 2/2018
View original content with
multimedia:http://www.prnewswire.com/news-releases/mallinckrodt-earns-somerset-county-planning-board-land-development-honor-300601326.html
SOURCE Mallinckrodt Pharmaceuticals